gms | German Medical Science

Introduction: Ixekizumab (IXE) and secukinumab (SECU) are IgG4 and IgG1 monoclonal antibodies inhibiting interleukin-17A (IL-17A) approved for multiple indications including PsA. Real-world data on the effectiveness of IL-17A inhibitors for the management of PsA domains is scarce. PRO-SPIRIT aims to investigate the real-world effectiveness of b/tsDMARDs in the treatment of PsA.

Objective: To describe the effectiveness of IXE and SECU in the treatment of PsA patients at 12-months within the PRO-SPIRIT study.

Methods: PRO-SPIRIT evaluates the persistence at 24 months among PsA patients who initiated or switched to new b/tsDMARDs in 5 European countries, and Canada. This analysis focuses on patients receiving either IXE or SECU. Patient characteristics were collected at baseline (BL) while clinical measures and patient related outcomes were collected at baseline, 3, 6, 12, 18, and 24 months. Results after 12 months are presented descriptively. Missing values were imputed.

Results: At baseline, patient characteristics were comparable, except for prior b/tsDMARD failure, which was reported in 70.3%, 53.5%, and 80.8% of patients on IXE 80 mg, SECU 150 mg, and SECU 300 mg, respectively (and subsequently reported in that order, herein) (Table 1 [Tab. 1]). At 12 months, change from baseline (CFB) in TJC was -5.5, -4.6, and -4.5; CFB in SJC was -3.1, -3.3, and -1.1, and CFB in cDAPSA was -12.5, -12.8, and -7.3. Minimal disease activity (MDA) was achieved by 23.6%, 35.9%, and 10.0% of patients with body surface area (BSA) <3% at BL and 30.0%, 25.0%, and 16.0% of patients with BSA ≥3% at BL.

Conclusion: Ixekizumab demonstrated similar joint, skin, and composite outcomes (cDAPSA and MDA) effectiveness despite a higher proportion of patients with previous treatment failures than SECU 150 and better than SECU 300. These findings align with those of the 3-month time point* confirming long-term efficacy of IXE across PsA domains.

*Effectiveness of IXE at 3 months was submitted at EULAR 2024.

Disclosures: Klaus Krueger received payment or honoraria from Lilly and Company as well as consultation fees and clinical trial payments from Eli Lilly and Company. Rieke Alten received payment or honoraria for speakers bureaus from AbbVie, Amgen, BMS, Celltrion, Chugai, Galapagos, Gilead, Janssen, Eli Lilly and Company, Mylan/Viatris, Novartis, Pfizer, Roche, and UCB; consulting fees from AbbVie, Amgen, BMS, Celltrion, Chugai, Galapagos, Gilead, Janssen, Eli Lilly and Company, Mylan/Viatris, Novartis, Pfizer, Roche, and UCB; and support for attending meetings and/or travel from AbbVie, Amgen, BMS, Celltrion, Chugai, Galapagos, Gilead, Janssen, Eli Lilly and Company, Mylan/Viatris, Novartis, Pfizer, Roche, and UCB. Eva Christina Schwaneck has received grants from Medac and Fresenius; consultation fees from Takeda, Medac, Amgen, and Galapagos; support for travel or attending meetings from Janssen, UCB, Medac, Abbvie, Takeda, and Otsuka; and has participated in participated on a data safety monitoring or advisory board for Amgen, Galapagos, and Abbvie.Hagen Russ is an employee and a shareholder of Eli Lilly and Company. Cedric Laedermann is an employee and a shareholder of Eli Lilly and Company. Marcus Ngantcha is an employee and a shareholder of Eli Lilly and Company. Angela Kill is an employee and a shareholder of Eli Lilly and Company.Stephanie Werner’s institution has received consulting fees from om Abbvie, Fresenius, Janssen-Cilag, Johnson & Johnson, Lilly, Novartis, and UCB; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Abbvie, Fresenius, Janssen-Cilag, Johnson & Johnson, Lilly, Novartis, UCB, and Rheuma-Zentrum Rhein Ruhr. Dennis McGonagle received payment or honoraria for speakers bureaus from Eli Lilly and Company, and support for attending meetings and/or travel from Eli Lilly and Company. Lars Erik Kristensen received fees for speaking from Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, Sanofi, Biogen, Forward Pharma, MSD, Novartis, Eli Lilly and Company, and Janssen pharmaceuticals, and is a shareholder in Novo Nordisk, Eli Lilly and Company, Merck, Novartis, and UCB.